Q3 2020 Sales Performance

Oncology R&D: strategy and scientific focus Maximise patient survival through transformational medicines gsk Immuno- Oncology Cancer Epigenetics Oncology Cell Therapy Synthetic Lethality Experimental Medicine Advance IO to next gen IO medicines, agnostic to modalities Establish epigenetic medicines for cancer Establish cell therapy for solid tumors Optimise use of PARP inhibitors and expand repertoire of synthetic lethal medicines Clinical biomarker strategy CDx Collaborative networks 46 46

View entire presentation